Mukhtar Ahmed

Life sciences organizations run a challenging gauntlet when it comes to clinical development.

The health sciences industry received some important and encouraging news from the US Food and Drug Administration in late June...

The advent of Accountable Care Organizations is causing providers to rethink their legacy financial models as they seek to effectively quantify and understand the clinical or financial experience of their patients.

The U.S. Food and Drug Administration opened the door to a new era of clinical trial management last summer when it released guidance for industry on clinical trial oversight and called for expanded use of risk-based monitoring.

Almost daily, we learn of stunning new advances in machine-to-machine (M2M) technologies in healthcare and life sciences, where sensors collect vast amounts of data that yield immediate and long-term insight, and that carry the promise of improved outcomes and quality of life.